UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

An Immune Atlas of Clear Cell Renal Cell Carcinoma

Cell, 2017-05, Vol.169 (4), p.736-749.e18

2017

Volltextzugriff (PDF)

Tumor beta2-microglobulin and HLA-A expression is increased by immunotherapy and can predict response to CIT in association with other biomarkers

Frontiers in immunology, 2024-02, Vol.15, p.1285049-1285049

2024

Volltextzugriff (PDF)

Expression profiling of human immune cell subsets identifies miRNA-mRNA regulatory relationships correlated with cell type specific expression

PloS one, 2012-01, Vol.7 (1), p.e29979-e29979

2012

Volltextzugriff (PDF)

Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren syndrome

Arthritis research & therapy, 2019-07, Vol.21 (1), p.175-175, Article 175

2019

Volltextzugriff (PDF)

Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

Haematologica (Roma), 2016-05, Vol.101 (5), p.e185-e188

2016

Volltextzugriff (PDF)

Case-control Indian buffet process identifies biomarkers of response to Codrituzumab

BMC cancer, 2019-03, Vol.19 (1), p.278-278, Article 278

2019

Volltextzugriff (PDF)

Pharmacodynamic Monitoring of RO5459072, a Small Molecule Inhibitor of Cathepsin S

Frontiers in immunology, 2017-07, Vol.8, p.806-806

2017

Volltextzugriff (PDF)

617 A Phase I study of a tumor-targeted, fibroblast activation protein (FAP)-CD40 agonist (RO7300490) in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A703-A703

2023

Volltextzugriff (PDF)

The catalytic PI3K isoforms p110γ and p110δ contribute to B cell development and maintenance, transformation, and proliferation

Journal of leukocyte biology, 2010-06, Vol.87 (6), p.1083-1095

2010

Volltextzugriff (PDF)

Impaired Immune Responses and Prolonged Allograft Survival in Sly1 Mutant Mice

Molecular and Cellular Biology, 2005-11, Vol.25 (21), p.9646-9660

2005

Volltextzugriff (PDF)

The orphan adapter protein SLY1 as a novel anti-apoptotic protein required for thymocyte development

BMC immunology, 2009-07, Vol.10 (1), p.38-38, Article 38

2009

Volltextzugriff (PDF)

Biomarker Technologies to Support Early Clinical Immuno-oncology Development: Advances and Interpretation

Clinical cancer research, 2021-08, Vol.27 (15), p.4147-4159

2021

Volltextzugriff (PDF)

Facts and Hopes on Biomarkers for Successful Early Clinical Immunotherapy Trials: Innovative Patient Enrichment Strategies

Clinical cancer research, 2024-04, Vol.30 (8), p.1448-1456

2024

Volltextzugriff (PDF)

Cathepsin S inhibition suppresses autoimmune-triggered inflammatory responses in macrophages

Biochemical pharmacology, 2017-12, Vol.146, p.151-164

2017

Volltextzugriff (PDF)

Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma

Journal of hepatology, 2016-08, Vol.65 (2), p.289-295

2016

Volltextzugriff (PDF)

Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer

Cancer discovery, 2018-04, Vol.8 (4), p.395-402

2018

Volltextzugriff (PDF)

SLy1 regulates T‐cell proliferation during Listeria monocytogenes infection in a Foxo1‐dependent manner

European journal of immunology, 2015-11, Vol.45 (11), p.3087-3097

2015

Volltextzugriff (PDF)

Abstract 2780: Loss of tumor HLA-A and B2M expression and association with biomarkers and clinical outcome

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.2780-2780

2022

Volltextzugriff (PDF)

Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab

Oncotarget, 2018-02, Vol.9 (12), p.10436-10444

2018

Volltextzugriff (PDF)

Abstract 3944: Combining tumor glypican-3 expression and CD16 Expression on NK cells from peripheral blood to identify patients responding to codrituzumabGC33RO5137382

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3944-3944

2016

Volltextzugriff (PDF)

Abstract 3944: Combining tumor glypican-3 expression and CD16 Expression on NK cells from peripheral blood to identify patients responding to codrituzumab/GC33/RO5137382

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3944-3944

2016

Volltextzugriff (PDF)

Reduced notch activity is associated with an impaired marginal zone B cell development and function in Sly1 mutant mice

Molecular immunology, 2009-02, Vol.46 (5), p.969-977

2009

Volltextzugriff (PDF)

CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3016-3016

2015

Volltextzugriff (PDF)

1 – 25 von 136

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(113)
Mit Volltextzugriff
(115)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

An Immune Atlas of Clear Cell Renal Cell Carcinoma

Tumor beta2-microglobulin and HLA-A expression is increased by immunotherapy and can predict response to CIT in association with other biomarkers

Expression profiling of human immune cell subsets identifies miRNA-mRNA regulatory relationships correlated with cell type specific expression

Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren syndrome

Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

Case-control Indian buffet process identifies biomarkers of response to Codrituzumab

Pharmacodynamic Monitoring of RO5459072, a Small Molecule Inhibitor of Cathepsin S

617 A Phase I study of a tumor-targeted, fibroblast activation protein (FAP)-CD40 agonist (RO7300490) in patients with advanced solid tumors

The catalytic PI3K isoforms p110γ and p110δ contribute to B cell development and maintenance, transformation, and proliferation

Impaired Immune Responses and Prolonged Allograft Survival in Sly1 Mutant Mice

The orphan adapter protein SLY1 as a novel anti-apoptotic protein required for thymocyte development

Biomarker Technologies to Support Early Clinical Immuno-oncology Development: Advances and Interpretation

Facts and Hopes on Biomarkers for Successful Early Clinical Immunotherapy Trials: Innovative Patient Enrichment Strategies

Cathepsin S inhibition suppresses autoimmune-triggered inflammatory responses in macrophages

Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma

Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer

SLy1 regulates T‐cell proliferation during Listeria monocytogenes infection in a Foxo1‐dependent manner

Abstract 2780: Loss of tumor HLA-A and B2M expression and association with biomarkers and clinical outcome

Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab

Abstract 3944: Combining tumor glypican-3 expression and CD16 Expression on NK cells from peripheral blood to identify patients responding to codrituzumabGC33RO5137382

Abstract 3944: Combining tumor glypican-3 expression and CD16 Expression on NK cells from peripheral blood to identify patients responding to codrituzumab/GC33/RO5137382

Reduced notch activity is associated with an impaired marginal zone B cell development and function in Sly1 mutant mice

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells

CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation

Suchergebnisse filtern